Drug
CHT101
CHT101 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting2
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
recruiting250%
not_yet_recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_1
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
NCT07809139
recruitingphase_1
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06914037
recruitingphase_1
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
NCT06730659
not_yet_recruitingphase_1
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
NCT06383507
Clinical Trials (4)
Showing 4 of 4 trials
NCT07809139Phase 1
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
NCT06914037Phase 1
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
NCT06730659Phase 1
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
NCT06383507Phase 1
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4